| Literature DB >> 33436735 |
Mitsuru Watanabe1, Yuri Nakamura1,2,3, Shinya Sato1, Masaaki Niino4, Hikoaki Fukaura5, Masami Tanaka6,7, Hirofumi Ochi8, Takashi Kanda9, Yukio Takeshita9, Takanori Yokota10, Yoichiro Nishida10, Makoto Matsui11, Shigemi Nagayama11, Susumu Kusunoki12, Katsuichi Miyamoto12, Masanori Mizuno13, Izumi Kawachi14,15, Etsuji Saji14, Takashi Ohashi16, Shun Shimohama17, Shin Hisahara17, Kazutoshi Nishiyama18, Takahiro Iizuka18, Yuji Nakatsuji19,20, Tatsusada Okuno19, Kazuhide Ochi21, Akio Suzumura22, Ken Yamamoto23, Yuji Kawano1,24, Shoji Tsuji25, Makoto Hirata26, Ryuichi Sakate26, Tomonori Kimura26, Yuko Shimizu27, Akiko Nagaishi28, Kazumasa Okada29, Fumie Hayashi1, Ayako Sakoda1,2, Katsuhisa Masaki1, Koji Shinoda1, Noriko Isobe1,30, Takuya Matsushita1, Jun-Ichi Kira31,32,33.
Abstract
HLA genotype-clinical phenotype correlations are not established for multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). We studied HLA-DRB1/DPB1 genotype-phenotype correlations in 528 MS and 165 NMOSD cases using Japan MS/NMOSD Biobank materials. HLA-DRB1*04:05, DRB1*15:01 and DPB1*03:01 correlated with MS susceptibility and DRB1*01:01, DRB1*09:01, DRB1*13:02 and DPB1*04:01 were protective against MS. HLA-DRB1*15:01 was associated with increased optic neuritis and cerebellar involvement and worsened visual and pyramidal functional scale (FS) scores, resulting in higher progression index values. HLA-DRB1*04:05 was associated with younger onset age, high visual FS scores, and a high tendency to develop optic neuritis. HLA-DPB1*03:01 increased brainstem and cerebellar FS scores. By contrast, HLA-DRB1*01:01 decreased spinal cord involvement and sensory FS scores, HLA-DRB1*09:01 decreased annualized relapse rate, brainstem involvement and bowel and bladder FS scores, and HLA-DRB1*13:02 decreased spinal cord and brainstem involvement. In NMOSD, HLA-DRB1*08:02 and DPB1*05:01 were associated with susceptibility and DRB1*09:01 was protective. Multivariable analysis revealed old onset age, long disease duration, and many relapses as independent disability risks in both MS and NMOSD, and HLA-DRB1*15:01 as an independent risk only in MS. Therefore, both susceptibility and protective alleles can influence the clinical manifestations in MS, while such genotype-phenotype correlations are unclear in NMOSD.Entities:
Year: 2021 PMID: 33436735 PMCID: PMC7804194 DOI: 10.1038/s41598-020-79833-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379